What's keeping less expensive versions of biologic drugs off the U.S. market?

Описание к видео What's keeping less expensive versions of biologic drugs off the U.S. market?

We look at a revolutionary class of drugs called "biologics." Americans have been paying more for their benefits than patients in Europe or Asia some say, because the "generic" versions or "biosimilars" have not hit the U.S. market. Dr. Emily Senay looks into why there's a delay and when American consumers can expect discounts.

Комментарии

Информация по комментариям в разработке

Похожие видео